Endoscopic therapy of Barrett's esophagus

Current Opinion in Gastroenterology

Volumn 25, Issue 5, 2009, Pages 405-411

  Pech, Oliver ^a   Ell, Christian ^a  

^a HSK Wiesbaden ^*  (Germany)

Author keywords

Adenocarcinoma; Barrett's esophagus; Endoscopic resection; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; BIOLOGICAL MARKER;

BARRETT ESOPHAGUS; BLOOD VESSEL; CANCER DIAGNOSIS; CANCER INVASION; CANCER REGRESSION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE COURSE; DISEASE SEVERITY; ENDOSCOPIC SURGERY; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS INJURY; ESOPHAGUS MUCOSA; ESOPHAGUS STRICTURE; ESOPHAGUS TUMOR; FOLLOW UP; HISTOLOGY; HUMAN; LYMPH VESSEL; PHOTODYNAMIC THERAPY; POSTOPERATIVE COMPLICATION; RADIOFREQUENCY ABLATION; RECURRENT CANCER; REVIEW; RISK FACTOR; TREATMENT INDICATION;

BARRETT ESOPHAGUS; CATHETER ABLATION; ESOPHAGOSCOPY; HUMANS; PHOTOCHEMOTHERAPY;

EID: 69749107566     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32832d9b71     Document Type: Review

References (43)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97:142-146. (Pubitemid 40277094)
2. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000; 95:1669-1676. (Pubitemid 30485000)
3. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-1639. (Pubitemid 32523482)
4. Fountoulakis A, Zafirellis KD, Dolan K, et al. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg 2004;91:997-1003. (Pubitemid 39070814)
5. Aldulaimi DM, Cox M, Nwokolo CU, Loft DE. Barrett's surveillance is worth-while and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur J Gastroenterol Hepatol 2005; 17:943-950. (Pubitemid 41192133)
6. Pech O, May A, Rabenstein T, Ell C. Endoscopic resection of early oesophageal cancer. Gut 2007; 56:1625-1634. (Pubitemid 350033204)
7. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999; 94:2037-2042.
8. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92:212-215.
9. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119:333-338.
10. Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-797.
11. Koop H, Schepp W, Muller-Lissner S, et al. Consensus conference of the DGVS on gastroesophageal reflux. Z Gastroenterol 2005; 43:163-164. (Pubitemid 40332908)
12. Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006;63:570-580.
13. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 2006;55:442.
14. Wani S, Puli SR, Shaheen NJ, et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009; 104:502-513.
15. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-1609. (Pubitemid 32523480)
16. Pech O, Vieth M, Schmitz D, et al. Conclusions from the histological diagnosis of low grade intraepithelial neoplasia in Barrett's oesophagus. Scand J Gastroenterol 2007; 42:682-688. (Pubitemid 46763591)
17. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-2848.
18. Buskens CJ, Westerterp M, Lagarde SM, et al. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 2004;60:703-710. (Pubitemid 39550926)
19. Stein HJ, Feith M, Bruecher BLDM, et al. Early esophageal squamous cell and adenocarcinoma: pattern of lymphatic spread and prognostic factors for long term survival after surgical resection. Ann Surg 2005; 242:566-573. (Pubitemid 41428652)
20. Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007; 65:3-10. (Pubitemid 44932158)
21. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57:1200-1206. This is the first publication providing long-termresults for the endoscopic treatment of patients with HGIN and mucosal Barrett's carcinoma in a large group of patients. Results also suggest that ablative treatment of the remaining nondysplastic Barrett's epithelium can significantly reduce the rate of recurrent neoplasia.
22. Barr H, Shepherd NA, Dix A, et al. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996; 348:584-585. (Pubitemid 26283891)
23. Manner H, May A, Pech O, et al. Early Barrett's carcinoma with 'low-risk' submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol 2008; 103:2589-2597. The results of this study suggest that endoscopic resection seems to be well tolerated also in patients with incipient infiltration of the submucosal layer (pT1sm1) without further risk factors.
24. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998; 114:448-455. (Pubitemid 28143291)
25. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49:1-7. (Pubitemid 29076815)
26. Pech O, Gossner L, May A, et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 2005; 62:24-30. (Pubitemid 40922436)
27. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005; 62:488-498.
28. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007; 66:460-468. (Pubitemid 47304412)
29. Bronner MP, Overholt BF, Taylor SL, et al. Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia. Gastroenterology 2009; 136:56-64. This large multicenter trial was able to demonstrate that squamous reepithelialization after PDT was not a safety concern. The highest degree of neoplasia was never found underneath neosquamous epithelium only.
30. Prasad GA, Wang KK, Halling KC, et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 2008;135:370-379.
31. Yachimski P, Puricelli WP, Nishioka NS. Patient predictors of esophageal stricture development after photodynamic therapy. Clin Gastroenterol Hepatol 2008; 6:302-308.
32. Prasad GA, Wang KK, Buttar NS, et al. Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 2007; 65:60-66. (Pubitemid 44917966)
33. Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007; 65:185-195. (Pubitemid 46157125)
34. Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc 2008; 68:35-40. This study demonstrated that RFA of patients with HGIN seems to be well tolerated and effective in multiple US centers. HGIN could be eradicated in 90% of patients.
35. Shaheen NJ, Sharma P, Overholt RF, et al. A randomized, multicenter, sham-controlled trial of radiofrequency ablation for subjects with Barrett's esophagus containing dysplasia. N Engl J Med (in press). This trial was able to show in a prospective sham-controlled trial that RFA is significantly more effective than sham treatment. However, in only 10 out of 15 patients, HGIN could be successfully eradicated.
36. Gondrie JJ, Pouw RE, Sondermeijer C, et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008; 40:370-379. (Pubitemid 351696373)
37. Gondrie JJ, Pouw RE, Sondermeijer C, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series in 11 patients. Endoscopy 2008; 40:359-369. (Pubitemid 351696372)
38. Peters FP, Kara MA, Rosmolen WD, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol 2006; 101:1449-1457.
39. Pouw RE, Peters FP, Sempoux C, et al. Stepwise radical endoscopic resection for Barrett's esophagus with early neoplasia: report on a Brussels' cohort. Endoscopy 2008; 40:892-898.
40. Kakushima N, Yahagi N, Fujishiro M, et al. Efficacy and safety of endoscopic submucosal dissection for tumors of the esophagogastric junction. Endoscopy 2006; 38:170-174. (Pubitemid 43286395)
41. Yoshinaga S, Gotoda T, Kusano C, et al. Clinical impact of endoscopic submucosal dissection for superficial adenocarcinoma located at the esophagogastric junction. Gastrointest Endosc 2008; 67:202-209. (Pubitemid 351146617)
42. Konda VJ, Ross AS, Ferguson MK, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol 2008; 6:159-164. This study demonstrates that 12.7% of patients with HGIN undergoing esophagectomy have submucosal Barrett's cancer. Those data nicely show that endoscopic resection of all localizable neoplastic lesions in Barrett's esophagus should be treated by endoscopic resection in order to obtain a specimen for histological work up. Ablative treatment would be an undertreatment in more than 10% of patients with HGIN.
43. Pech O, Gossner L, Manner H, et al. Prospective evaluation of the macroscopic types and location of early Barrett's neoplasia in 380 lesions. Endoscopy 2007; 39:588-593. (Pubitemid 47098994)